prikaz prve stranice dokumenta Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
  Download
PDF 413.59 KB
Scientific paper - Original scientific paper
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
Blood Advances, 7 (2023), 11; 2645-2655. https://doi.org/10.1182/bloodadvances.2022009578
van Doesum, Jaap A.; Salmanton-García, Jon; Marchesi, Francesco; Di Blasi, Roberta; Falces-Romero, Iker; Cabirta, Alba; Farina, Francesca; Besson, Caroline; Weinbergerová, Barbora; Van Praet, Jens; Schönlein, Martin; López-García, Alberto; Lamure, Sylvain; Guidetti, Anna; De Ramón-Sánchez, Cristina; Batinić, Josip; Gavriilaki, Eleni; Tragiannidis, Athanasios; Tisi, Maria Chiara; Plantefeve, Gaëtan; Petzer, Verena; Ormazabal-Vélez, Irati; Marques de Almeida, Joyce; Marchetti, Monia; Maertens, Johan; Machado, Marina; Kulasekararaj, Austin; Hernández-Rivas, José-Ángel; Gomes da Silva, Maria; Fernández, Noemí; Espigado, Ildefonso; Drgoňa, Ľuboš; Dragonetti, Giulia; Metafuni, Elisabetta; Calbacho, Maria; Blennow, Ola; Wolf, Dominik; van Anrooij, Bjorn; Nunes Rodrigues, Raquel; Nordlander, Anna; Martín-González, Juan-Alberto; Liévin, Raphaël; Jiménez, Moraima; Gräfe, Stefanie K.; García-Sanz, Ramón; Córdoba, Raúl; Rahimli, Laman; van Meerten, Tom; Cornely, Oliver A.; Pagano, Livio More authors...

Cite this document

van Doesum, J. A., Salmanton García, J., Marchesi, F., Di Blasi, R., Falces Romero, I., Cabirta, A. ... Pagano, L. (2023). Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Advances, 7. (11), 2645-2655. doi: 10.1182/bloodadvances.2022009578

van Doesum, Jaap A., et al. "Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey." Blood Advances, vol. 7, no. 11, 2023, pp. 2645-2655. https://doi.org/10.1182/bloodadvances.2022009578

van Doesum, Jaap A., Jon Salmanton García, Francesco Marchesi, Roberta Di Blasi, Iker Falces Romero, Alba Cabirta, Francesca Farina, et al. "Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey." Blood Advances 7, no. 11 (2023): 2645-2655. https://doi.org/10.1182/bloodadvances.2022009578

van Doesum, J. A., et al. (2023) 'Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey', Blood Advances, 7(11), pp. 2645-2655. doi: 10.1182/bloodadvances.2022009578

van Doesum JA, Salmanton García J, Marchesi F, Di Blasi R, Falces Romero I, Cabirta A, and sur.. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Advances [Internet]. 2023 June 13 [cited 2024 December 25];7(11):2645-2655. doi: 10.1182/bloodadvances.2022009578

J. A. van Doesum, et al., "Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey", Blood Advances, vol. 7, no. 11, pp. 2645-2655, June 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:269631. [Accessed: 25 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
AuthorJaap A. van Doesum
AuthorJon Salmanton-García
AuthorFrancesco Marchesi
AuthorRoberta Di Blasi
AuthorIker Falces-Romero
AuthorAlba Cabirta
AuthorFrancesca Farina
AuthorCaroline Besson
AuthorBarbora Weinbergerová
AuthorJens Van Praet
AuthorMartin Schönlein
AuthorAlberto López-García
AuthorSylvain Lamure
AuthorAnna Guidetti
AuthorCristina De Ramón-Sánchez
AuthorJosip Batinić
AuthorEleni Gavriilaki
AuthorAthanasios Tragiannidis
AuthorMaria Chiara Tisi
AuthorGaëtan Plantefeve
AuthorVerena Petzer
AuthorIrati Ormazabal-Vélez
AuthorJoyce Marques de Almeida
AuthorMonia Marchetti
AuthorJohan Maertens
AuthorMarina Machado
AuthorAustin Kulasekararaj
AuthorJosé-Ángel Hernández-Rivas
AuthorMaria Gomes da Silva
AuthorNoemí Fernández
AuthorIldefonso Espigado
AuthorĽuboš Drgoňa
AuthorGiulia Dragonetti
AuthorElisabetta Metafuni
AuthorMaria Calbacho
AuthorOla Blennow
AuthorDominik Wolf
AuthorBjorn van Anrooij
AuthorRaquel Nunes Rodrigues
AuthorAnna Nordlander
AuthorJuan-Alberto Martín-González
AuthorRaphaël Liévin
AuthorMoraima Jiménez
AuthorStefanie K. Gräfe
AuthorRamón García-Sanz
AuthorRaúl Córdoba
AuthorLaman Rahimli
AuthorTom van Meerten
AuthorOliver A. Cornely
AuthorLivio Pagano
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBlood Advances
Numberingvol. 7, no. 11, pp. 2645-2655
p-ISSN2473-9529
e-ISSN2473-9537
DOIhttps://doi.org/10.1182/bloodadvances.2022009578
URN:NBNurn:nbn:hr:105:269631
Publication2023-06-13
Document URLhttps://ashpublications.org/bloodadvances/article/7/11/2645/495340/Impact-of-SARS-CoV-2-vaccination-and-monoclonal
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2023-11-24 11:06:59